Shibuya Corporation and Shinsei Bank joined existing investors in the liver disease therapy developer to buy $11.5m in convertible bonds.
Belgium-based liver disease therapy developer Promethera Biosciences secured €9.3m ($11.5m) in convertible bond financing yesterday from investors including packaging system manufacturer Shibuya Corporation.
Shinsei Corporate Investment, the corporate venturing arm of financial services firm Shinsei Bank, also participated in the issue, as did unnamed existing investors.
Founded in 2009, Promethera Biosciences develops cell-based therapies for liver diseases. Its lead asset, HepaStem, has entered phase 2 clinical trials for acute-on-chronic liver failure and non-alcoholic fatty liver disease, also known as non-alcoholic…
